Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Update

Acasti Pharma Inc. (NASDAQ:ACST) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 3,800 shares, an increase of 171.4% from the March 31st total of 1,400 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 25,600 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, Craig Hallum initiated coverage on Acasti Pharma in a report on Wednesday, February 7th. They issued a “buy” rating and a $6.00 price objective on the stock.

Acasti Pharma Stock Up 1.0 %

Shares of ACST opened at $2.93 on Friday. The firm has a market cap of $27.53 million, a price-to-earnings ratio of -0.58 and a beta of 1.49. The company’s fifty day moving average is $3.33 and its 200-day moving average is $2.74. Acasti Pharma has a 12 month low of $1.72 and a 12 month high of $3.84.

Acasti Pharma (NASDAQ:ACST) last posted its earnings results on Monday, February 12th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. As a group, research analysts predict that Acasti Pharma will post -1.44 earnings per share for the current fiscal year.

About Acasti Pharma

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.